Navigation Links
Par Pharmaceutical Reports Second Quarter 2008 Results
Date:8/7/2008

competition on the Company's generic products, decreased net sales of Megace(R) ES, and lower royalty income.

Revenues for the generic products division during the three month period decreased 36.4% to $92.9 million compared with the same period in 2007 due to competitive pressure, including for fluticasone, ranitidine HCl syrup, cabergoline, and a decline in many of the Company's other products due to pricing pressures as well as lower royalties driven from ondansetron ODT. Partially offsetting the decreases were increased sales of metoprolol resulting from the launch of additional strengths in the third quarter of 2007 and various amoxicillin products. Second quarter 2008 revenue for Strativa decreased to $20.0 million from $21.6 million in the prior year due to decreased net sales of Megace(R) ES.

Par's second quarter gross margin was 22.2% of sales, compared with 33.7% in 2007. This decrease is primarily attributed to increased sales of lower margin metoprolol, lower royalty income, lower sales of higher margin products such as propranolol, and a decline in many of the Company's other generic products due to pricing pressures, tempered by higher relative sales of Megace(R) ES. The gross margin rate for Strativa was 79.3% in the second quarter of 2008 compared with 72.5% in the same period in 2007.

Research and development (R&D) expense increased $1.7 million or 11.8% to $16.0 million in the second quarter of 2008, driven primarily by an increase in on-going development costs associated with the expansion of Par's generic portfolio and includes Strativa's research costs related to the development of Zensana(TM) and an initial payment related to the in-licensing agreement with MonoSol Rx.

Second quarter selling, general and administrative (SG&A) expense increased 7.9% to $36.7 million compared with the second quarter of 2007. The increase was driven by legal fees related to ongoing litigation, including Paragraph IV litigation costs. Th
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. Memory Pharmaceuticals to Announce Second Quarter 2008 Results on Wednesday, August 13, 2008
3. Watson Pharmaceuticals Reports Second Quarter 2008 Results
4. XTELL Launches its Commercial Biorepository Services for Research and Pharmaceutical Companies
5. Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results
6. Arena Pharmaceuticals Announces Second Quarter 2008 Financial Results and Recent and Second Quarter Highlights
7. Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer
8. Prometic reaches understanding for commercialisation of several biopharmaceutical products and strategic investment
9. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Two Investment Conferences During the Month of August 2008
10. Kowa Company, Ltd. Acquires ProEthic Pharmaceuticals, Inc.
11. Lilly Reaffirms Purchase Offer for SGX Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... (PRWEB) December 23, 2014 On ... law H.R. 83, the Omnibus and Continuing Resolution ... time, made hydrocephalus a condition eligible to receive ... (CDMRP) administered by the Department of Defense (DoD). ... its allies on Capitol Hill, is celebrating this ...
(Date:12/24/2014)... 2014 Pipette.com announces their Holiday ... can submit their #HolidayInTheLab pictures for a chance to ... , For those struggling to think of a holiday ... in the Lab Contest provides the ideal holiday presents. ... to send pictures of their chemistree, holiday sweaters, as ...
(Date:12/24/2014)... 2014  Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... Clinical Trial Application (CTA) with the United ... seeking regulatory approval to initiate clinical trials for the ... Contingent on the Company receiving CTA regulatory approval, ... to assess the safety, tolerability and dose escalation of ...
(Date:12/22/2014)... CHAPEL HILL, N.C. , Dec. 22, 2014 ... ALNE) today announced that it has signed a ... biotechnology company that has developed and patented a ... and medical diagnostics products that enable rapid on-site ... and alcohol use/abuse and health issues in an ...
Breaking Biology Technology:Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3ALNE Announces Intention To Acquire BioTechPharma 2
... Covance Inc. ... has joined the company as vice president and chief ... years of pharmaceutical industry experience, including bioanalytical research, translational ... marketing, and business development strategy for Covance,s bioanalytical services. ...
... Laboratories, Ltd. (NYSE Amex: CPD ) has ... Ltd. (Sun Pharma), immediately following Sun Pharma,s recently received ... for its Abbreviated New Drug Application (ANDA) for generic ... androgen receptor inhibitor indicated for use in combination therapy ...
... , , Immunotec Receives NHPD/Health Canada Authorization ... of the Cysteine-Rich Whey Protein Isolate (Immunocal(R)) in, ... and Inflammatory Cytokine Levels in Elderly Persons: ... MONTREAL, July 7 /PRNewswire-FirstCall/ - Immunotec Inc. (TSX-V: IMM) announced ...
Cached Biology Technology:Covance Appoints Dr. Steven M. Michael as Vice President and Chief Scientific Officer of Global Bioanalytical Services 2Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Casodex(R) Tablets 22009: Immunotec announces important clinical research initiative: New study to be launched with the goal of improving the quality of the aging process 22009: Immunotec announces important clinical research initiative: New study to be launched with the goal of improving the quality of the aging process 3
(Date:12/10/2014)... SUNNYVALE, California , December 9, 2014 /PRNewswire/ ... Integrate with ITN,s BCARD Platform ... secure, cloud-based enterprise meeting scheduling solutions for business-to-business ... International, the world leader in mobile near-field communication ... solutions.      (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , ...
(Date:12/3/2014)... GLENDALE, Ariz. , Dec. 2, 2014 ... biometric hand readers, Inception Technologies is pleased to announce ... it easier for customers to collect the workforce data ... the problems that have been left by existing readers. ... to user interface, connectivity and modern technology. Older models ...
(Date:11/21/2014)... JOSE, Calif. , Nov. 20, 2014   ... global leader in microcontroller (MCU) and touch technology solutions, ... digital temperature sensors with the widest V cc ... delivers higher temperature accuracy and faster I 2 C ... registers and serial EEPROM memory making them ideal for ...
Breaking Biology News(10 mins):Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Inception Technologies to Release New Biometric Reader 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4
... have developed a new tool that uses natural "fingerprints" ... the environment. The research is published in ... & Technology . Mercury is a naturally occurring ... environment each year from human-generated sources such as incinerators, ...
... Valley Virus-001, reveals that it is unlike any other known ... designation as a separate genus "Senecavirus." The new study reveals ... golf ballone with uneven divets and raised spikesand the RNA ... like a whiffleball. "It is not at all like ...
... physical activity during pregnancy does not contribute to low ... reduce the risk of complications, according to a Michigan ... first-ever guidelines on physical activity. Kinesiology ... Erin Kuffel wrote the section on pregnancy and postpartum ...
Cached Biology News:'Fingerprinting' method tracks mercury emissions from coal 2'Fingerprinting' method tracks mercury emissions from coal 3Scripps research team solves structure of 'beneficial' virus 2Guidelines urge physical activity during pregnancy 2